METROPOLITAN LIFE INSURANCE CO/NY - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.

Quarter-by-quarter ownership
METROPOLITAN LIFE INSURANCE CO/NY ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$12,443
-47.8%
1,1140.0%0.00%0.0%
Q2 2023$23,840
-47.1%
1,1140.0%0.00%
-50.0%
Q1 2023$45,050
-23.9%
1,114
-12.5%
0.00%
-33.3%
Q4 2022$59,220
-10.3%
1,2730.0%0.00%0.0%
Q3 2022$66,031
+9.7%
1,2730.0%0.00%0.0%
Q2 2022$60,175
-33.6%
1,2730.0%0.00%0.0%
Q1 2022$90,612
-77.6%
1,273
-76.5%
0.00%
-40.0%
Q4 2021$404,709
+31.6%
5,4120.0%0.01%
+25.0%
Q3 2021$307,456
+31.5%
5,412
+1.9%
0.00%
+33.3%
Q2 2021$233,781
-10.8%
5,312
-0.0%
0.00%
-25.0%
Q1 2021$262,037
+17.1%
5,3130.0%0.00%
+33.3%
Q4 2020$223,677
-8.0%
5,3130.0%0.00%
-25.0%
Q3 2020$243,229
-26.3%
5,313
-19.2%
0.00%
-33.3%
Q2 2020$330,131
+13.0%
6,575
+15.7%
0.01%0.0%
Q1 2020$292,225
-13.6%
5,682
+3.8%
0.01%0.0%
Q4 2019$338,184
+2.8%
5,4740.0%0.01%0.0%
Q3 2019$328,878
-28.8%
5,4740.0%0.01%
-25.0%
Q2 2019$461,896
-11.7%
5,4740.0%0.01%
-11.1%
Q1 2019$522,876
+34.9%
5,4740.0%0.01%
+12.5%
Q4 2018$387,723
-17.1%
5,4740.0%0.01%0.0%
Q3 2018$467,808
-99.9%
5,4740.0%0.01%
-20.0%
Q2 2018$634,437,000
+56.8%
5,474
+9.4%
0.01%
+66.7%
Q1 2018$404,712,000
+137557.1%
5,0020.0%0.01%
+50.0%
Q4 2017$294,000
-41.0%
5,002
-53.0%
0.00%
+33.3%
Q3 2017$498,000
+18.6%
10,642
-8.7%
0.00%0.0%
Q2 2017$420,000
+17.0%
11,6600.0%0.00%
+50.0%
Q1 2017$359,000
-8.2%
11,6600.0%0.00%
-33.3%
Q4 2016$391,000
+26.1%
11,6600.0%0.00%
+50.0%
Q3 2016$310,000
+20.6%
11,6600.0%0.00%0.0%
Q2 2016$257,000
-24.9%
11,6600.0%0.00%
-33.3%
Q1 2016$342,000
-11.2%
11,6600.0%0.00%0.0%
Q4 2015$385,000
-8.6%
11,6600.0%0.00%0.0%
Q3 2015$421,000
-17.5%
11,660
+3.0%
0.00%
-25.0%
Q2 2015$510,000
+102.4%
11,325
+37.7%
0.00%
+100.0%
Q1 2015$252,000
-39.7%
8,2220.0%0.00%
-33.3%
Q4 2014$418,000
+28.6%
8,2220.0%0.00%
+50.0%
Q3 2014$325,000
-8.2%
8,2220.0%0.00%0.0%
Q2 2014$354,0008,2220.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 862,848$42,556,00014.73%
Fairmount Funds Management LLC 171,147$8,441,0003.56%
ARMISTICE CAPITAL, LLC 1,648,000$81,279,0001.87%
FARALLON CAPITAL MANAGEMENT LLC 1,995,000$98,393,0000.49%
Jackson Creek Investment Advisors LLC 21,409$1,056,0000.37%
Hennion & Walsh Asset Management, Inc. 113,940$5,620,0000.34%
Virtus ETF Advisers LLC 14,721$726,0000.31%
Granahan Investment Management 193,416$9,539,0000.20%
Yorktown Management & Research Co Inc 4,500$222,0000.18%
JACOBS LEVY EQUITY MANAGEMENT, INC 242,257$11,948,0000.09%
View complete list of ENANTA PHARMACEUTICALS INC shareholders